ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.
ImmVirX has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
ImmVirX's investors include OneVentures, Acorn Capital.
ImmVirX is headquartered in New Lambton, Australia.
ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.
ImmVirX is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ImmVirX — Funding & Investors." VCBacked, June 5, 2023, https://www.vcbacked.co/company/immvirx. Accessed October 2, 2026.
VCBacked. (2023). ImmVirX — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/immvirx
{{cite web |title=ImmVirX — Funding & Investors |url=https://www.vcbacked.co/company/immvirx |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated